NMPA
China — NMPA
Technical Review Guideline on Medical Device Cybersecurity (2022 rev.)
Authority
National Medical Products Administration
Enforced
2022
Legal framework
NMPA Cybersecurity Guideline + MLPS 2.0 + Data Security Law + PIPL
Scope
All medical devices with cybersecurity features: data storage, exchange, remote control or interfaces. Network type classification determines depth of evidence.
Pre-market
Cybersecurity description, risk analysis, network type classification, verification & validation in registration dossier.
Post-market
Annual self-assessment, incident reporting within 24h, software upgrade approvals required.
SBOM
RecommendedNot strictly required; component lists must appear in technical documentation.
Vulnerability disclosure
MIIT CNVD (China National Vulnerability Database) coordination required.
Penalty
Registration revocation, fines under DSL up to RMB 10M, criminal liability for serious data breaches.
Unique requirements
- 01MLPS 2.0 cybersecurity grading (Level 2 or 3 typical)
- 02Cross-border data transfer security assessment
- 03Chinese Legal Agent and registration via NMPA
- 04Software changes may trigger re-registration
Highlights
- Data localisation under PIPL
- MLPS 2.0 grading required
- Cross-border data transfer restrictions
Aligns with
Timeline
-
Jan 2017
First NMPA cybersecurity guideline
-
Sep 2021
DSL & PIPL effective
-
Mar 2022
Revised cybersecurity guideline
Key documents
NMPA head-to-head
Related markets
Frequently asked about China
Is SBOM required for medical devices in China?
Recommended. Not strictly required; component lists must appear in technical documentation.
What does NMPA require for pre-market cybersecurity?
Cybersecurity description, risk analysis, network type classification, verification & validation in registration dossier.
What are the post-market cybersecurity obligations under NMPA?
Annual self-assessment, incident reporting within 24h, software upgrade approvals required.
What is the penalty for non-compliance with NMPA cybersecurity rules?
Registration revocation, fines under DSL up to RMB 10M, criminal liability for serious data breaches.
How much of my FDA cybersecurity package is reusable in China?
Roughly 45% — an editorial estimate based on overlapping evidence requirements (threat model, SBOM, security risk assessment, pen-test report).